Catalent
Catalent’s SMARTag Technology
- Catalent’s SMARTag Technology, a full suite of proprietary tools including conjugation chemistry, linkers, and payloads, is rapidly becoming the platform of choice for drug developers to build superior bioconjugates.
- Leapfrog competition by partnering with Catalent’s experienced R&D team and leveraging our resources to execute a customized workplan for ADC discovery & development exceeding your goals for timeline, performance, and cost.
- Accelerate your timeline by acquiring an asset from Catalent’s pipeline of novel conjugates against a range of solid tumor indications all of which feature both proprietary antibodies and proprietary linker-payloads.
- SMARTag® Enhanced Conjugates feature new payload combinations, designed to improve efficacy and potency through the dual activities of cytotoxic and non-cytotoxic payloads ligated to a single ADC using our industry-recognized stable linkers.
- Based on technology originated by Prof. Carolyn Bertozzi (2022 Nobel Laureate, Chemistry), SMARTag Technology has been recognized Runner-Up for Best ADC Platform for the past 3 years (2022, 2023, 2024)
